Skip to content
Homepage
Category:
Globe Newswire
Posted Date:
June 8, 2026
Toobit Adds XLM to Fixed Earn Series with Limited-Time 60% APR
Toobit
June 8, 2026
Lim Meng Hoong: AI Is Entering a New Era of Scientific Infrastructure, Insights from Science x AI Summit 2026
MengHoong Intelligent Investment Academy
June 7, 2026
Macau Tea Beverage Brand ‘Cha Yu’ Redefines Local Flavors with Original Recipes and Signature Cloud Milk Tea
Cha Yu Limited
June 7, 2026
GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company
GNI Group Co., Ltd.
June 7, 2026
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
LENZ Therapeutics, Inc.
June 7, 2026
NVIDIA and SK hynix Announce Multiyear Technology Partnership to Advance Memory for AI Factories
NVIDIA
June 7, 2026
NAVER Expands AI Infrastructure With NVIDIA to Serve Surging Global AI Demand
NVIDIA
June 7, 2026
Entrata Collaborates with OpenAI to Define the Future of Autonomous Property Management
Entrata
June 7, 2026
SK Telecom and NVIDIA Build AI Infrastructure to Power Korea’s AI Innovation
NVIDIA
June 7, 2026
Diasome Presents Phase 2b Data Demonstrating HDV™-Insulin Lispro Maintains Glycemic Control While Reducing Hypoglycemia in Adults with Type 1 Diabetes
Diasome
June 7, 2026
GoHealth, Inc. to strengthen its position ahead of AEP 2026 through Restructuring Process supported by key stakeholders
GoHealth, Inc.
June 7, 2026
Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis
Zealand Pharma
June 7, 2026
Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity
Boehringer Ingelheim Limited
June 7, 2026
Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist
Antag Therapeutics
June 7, 2026
Prev
1
…
256
257
258
